HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome.
Apocrine carcinoma
Breast cancer
HER2
Outcome
Special types
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
05
02
2022
accepted:
17
03
2022
pubmed:
1
4
2022
medline:
14
5
2022
entrez:
31
3
2022
Statut:
ppublish
Résumé
Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+/APO and matched HER2+/NST cohort. We used the SEER database to explore the cohorts. Univariate and multivariate analyses were used to assess the survival. Based on ER and PR [steroid receptors/SR/] and HER2 status, we divided the cohorts to match the intrinsic molecular subtypes for comparisons. We retrieved 259 cases of HER2+/APO. Most HER2+/APO were SR negative (65%). HER2+/APO were more prevalent in the 80+ age group (24.7% vs. 15.7%, p < 0.001). HER2+/SR-/APO had a significantly lower histological grade than the HER2+/SR-/NST (p < 0.001). Breast cancer-related deaths were more prevalent in HER2+/NST (7.8% vs. 3.9%, p = 0.019). This was particularly evident between SR- subgroups (10.4% in HER2+/SR-/NST vs. 4.2% in HER2+/SR-/APO, p = 0.008) and was reaffirmed in breast cancer-specific survival in univariate analysis (p = 0.03). Other than race and SR status, HER2+/APO subgroups did not differ in clinicopathological parameters. Our study confirms the rarity of the APO and reveals that SR status in APO does not affect these patients' prognosis. HER2+/APO tumors tend to have a less aggressive phenotype and a more favorable outcome despite a markedly lower ER/PR positivity.
Identifiants
pubmed: 35355162
doi: 10.1007/s10549-022-06578-4
pii: 10.1007/s10549-022-06578-4
pmc: PMC9090698
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Estrogen
0
Receptors, Progesterone
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
523-533Informations de copyright
© 2022. The Author(s).
Références
Breast. 2013 Oct;22(5):761-6
pubmed: 23416046
Cancer Med. 2019 Dec;8(18):7523-7531
pubmed: 31642210
Br J Cancer. 2019 Apr;120(9):913-921
pubmed: 30899086
Ann Surg Oncol. 2021 Oct;28(10):5610-5616
pubmed: 34426884
J Surg Oncol. 2020 Nov;122(6):1232-1239
pubmed: 32668059
J Cancer. 2018 Jan 1;9(2):296-303
pubmed: 29344276
Clin Breast Cancer. 2013 Apr;13(2):95-102
pubmed: 23245877
Eur J Cancer. 2018 Jul;98:48-58
pubmed: 29870876
Bosn J Basic Med Sci. 2017 Feb 21;17(1):9-11
pubmed: 28027454
Clin Breast Cancer. 2018 Oct;18(5):e773-e780
pubmed: 29573977
Oncotarget. 2017 Apr 11;8(15):24579-24592
pubmed: 28445946
Breast J. 2018 Nov;24(6):1105-1108
pubmed: 30240079
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820943246
pubmed: 32677589
J Clin Pathol. 2019 Jan;72(1):7-11
pubmed: 30425121
J Clin Oncol. 2008 Jul 1;26(19):3153-8
pubmed: 18490649
Mod Pathol. 2020 Dec;33(12):2473-2482
pubmed: 32504034
Clin Breast Cancer. 2022 Jun;22(4):e576-e585
pubmed: 35027319
Histol Histopathol. 2013 Nov;28(11):1393-409
pubmed: 23771415
Pathol Res Pract. 1997;193(11-12):753-8
pubmed: 9521507
Clin Breast Cancer. 2013 Feb;13(1):31-9
pubmed: 23098574
Eur J Surg Oncol. 2018 Apr;44(4):420-428
pubmed: 29429597
Breast Cancer Res Treat. 2020 Nov;184(2):527-542
pubmed: 32794061
Hum Pathol. 2015 Sep;46(9):1350-9
pubmed: 26208846
Mod Pathol. 2010 May;23(5):644-53
pubmed: 20208479